Akouos, Inc. is a company dedicated to precise genetic medicine, developing gene therapies with the aim of restoring, enhancing, and safeguarding individuals' natural auditory function. Central to its strategy is an advanced genetic medicine platform, which incorporates a proprietary library of adeno-associated viral vectors and an innovative delivery method. The firm's leading experimental therapy is AK-OTOF, a gene therapy designed to treat hearing impairment caused by mutations in the OTOF gene. Additionally, Akouos is advancing AK-CLRN1 for the auditory symptoms linked to Usher syndrome type 3A (USH3A), and AK-antiVEGF for addressing vestibular schwannoma. The company's comprehensive genetic platform further addresses hearing loss related to genes essential for supporting cell function. Founded in 2016, Akouos, Inc. is headquartered in Boston, Massachusetts.